SCHEMBL4151317

SCHEMBL4151317

O=C(c1ccc(O)cc1O)N1CCC(Cc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SPR P35270 2/20 0.60
TACR3 P29371 1/20 0.57
CYP2C9 P11712 5/20 0.54
CYP2C19 P33261 5/20 0.54
MAPK14 Q16539 5/20 0.54
HTR2B P41595 3/20 0.54
GRIN2D O15399 4/20 0.54
GRIN3B O60391 4/20 0.54
GRIN1 Q05586 4/20 0.54
GRIN2A Q12879 4/20 0.54
GRIN2B Q13224 4/20 0.54
GRIN2C Q14957 4/20 0.54
GRIN3A Q8TCU5 4/20 0.54
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9785745 0.93 CYP2C9 (0.63) SPRCYP2C9CYP2C19MAPK14HTR2B
SCHEMBL4151901 0.88 SPR (0.62) SPRTACR3CYP2C9CYP2C19MAPK14
SCHEMBL4155107 0.83 HSP90AA1 (0.50) SPRHSP90AA1HSP90AB1
SCHEMBL4145949 0.83 GRIN2D (0.63) SPRCYP2C9CYP2C19MAPK14HTR2B
SCHEMBL4143776 0.81 CYP2C9 (0.54) SPRCYP2C9CYP2C19MAPK14HTR2B
SCHEMBL2729282 0.81 CYP2C9 (0.60) SPRCYP2C9CYP2C19MAPK14HTR2B
SCHEMBL4143175 0.79 HSP90AA1 (0.62) SPRHSP90AA1HSP90AB1
SCHEMBL5820252 0.78 CYP2C9 (0.77) CYP2C9CYP2C19MAPK14HTR2BGRIN2D
SCHEMBL4152644 0.78 SPR (0.45) SPRCYP2C9GRIN2BHSP90AA1HSP90AB1
SCHEMBL4155933 0.77 SPR (0.52) SPRGRIN1GRIN2BHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US claimed
EP-1879863-A1 AMIDE RESORCINOL COMPOUNDS Pfizer, Inc. (US) 2008-01-23 EP claimed
WO-2006117669-A1 AMIDE RESORCINOL COMPOUNDS PFIZER INC. (US) 2006-11-09 WO claimed
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US disclosed
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US disclosed
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US disclosed
EP-1879863-A1 AMIDE RESORCINOL COMPOUNDS Pfizer, Inc. (US) 2008-01-23 EP disclosed
WO-2006117669-A1 AMIDE RESORCINOL COMPOUNDS PFIZER INC. (US) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS HSP90AB1, HSP90AA1, HSP90AB2P SPR 906/4885TACR3 3743/4885CYP2C9 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.